Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...
For years, CRISPR Therapeutics (CRSP 1.25%) has been the type of stock investors might call a home run swing. The company ...
Eli Lilly's pipeline is an embarrassment of riches.
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...
2don MSN
New 'SMART' platform makes gene editing in hematopoietic stem cells more efficient and safer
A team of researchers led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has developed a ...
By Padmanabhan Ananthan June 3 (Reuters) - Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its ...
It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...
A team of researchers led by Luigi Naldini at the San Raffael Institute for Gene Therapy (SR-Tiget) has developed a new ...
Novel CRISPR-Cas9 treatments are proving effective in reversing disease for life. But ensuring their long-term safety will ...
The gene-editing niche of the biotech industry is gaining momentum, as various companies focused on these techniques -- which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results